Polyvalent VP2 Mosaic VLPs for IBDV Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for infectious bursal disease virus (IBDV) in poultry are costly, time-consuming to produce, and can lose potency due to the use of antigens from eggs or cell culture, leading to increased morbidity and mortality in poultry meat and egg production.
Innovation Solution
Development of polyvalent VP2 and mosaic virus-like particles (VLPs) comprising antigenically distinct VP2 monomers from various IBDV strains, which are co-expressed with VP3 using recombinant Baculoviruses in Sf9 cells to produce immunogenic particles that induce a protective immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If inactivated IBDV vaccines are prepared in young chicks, then the quality and quantity of antigen is superior, but the process is expensive and time consuming
Solution Approach 1:
The patent uses recombinant baculovirus to express viral proteins VP2 and VP3 in insect cells, creating a copy of the viral antigens without requiring live virus propagation in chicks. This produces high-quality antigens through controlled recombinant expression while eliminating the time-consuming and expensive chick inoculation process
Solution Approach 2:
The patent replaces the biological mechanical system of virus propagation in chick bursas with a controlled cell culture system using Sf9 insect cells and recombinant baculovirus. This substitution enables precise control over antigen production while maintaining high antigen quality through optimized expression conditions
2Manufacturing precision
If inactivated IBDV vaccines are prepared in young chicks, then the quality and quantity of antigen is superior, but the process is time consuming
Solution Approach 1:
The patent creates recombinant copies of viral antigens (VP2 and VP3 proteins) using baculovirus expression vectors in Sf9 cells. This copying approach produces high-quality antigens that match native viral proteins while dramatically reducing production time from weeks to days by eliminating the need for live virus propagation and chick incubation periods
Solution Approach 2:
The patent performs preliminary construction of recombinant baculovirus vectors containing the viral antigen genes before scaling up production. This preliminary preparation of expression systems allows for rapid, large-scale antigen production without the time-consuming steps of traditional chick-based vaccine preparation
3Adaptability or versatility
If antigens are produced in eggs or cell culture, then animal use issues are reduced, but the potency and efficacy of vaccines decreases
Solution Approach 1:
The patent replaces egg-based and traditional cell culture systems with recombinant baculovirus expression in Sf9 insect cells. This substitution maintains production flexibility while ensuring vaccine potency through controlled expression of authentic viral proteins with proper post-translational modifications, eliminating animal use issues simultaneously
Solution Approach 2:
The patent optimizes expression parameters including cell culture conditions, virus multiplicity of infection, and harvest timing to produce antigens with high potency and efficacy. By controlling these parameters in the recombinant system, the patent achieves vaccine reliability comparable to or exceeding traditional methods while providing production flexibility
Data Source
AI summary
Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.